Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DECRESCENDO: De-escalation in HER2+ Breast Cancer
NCT04675827Phase 2Terminated
- Sponsor
- Institut Jules Bordet
- Start
- Jan 2022
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies, Drug Delivery Systems
- Countries
- 6
01
Overview
Phase 2, open-label trial of trastuzumab + pertuzumab in breast cancer (2 arms), sponsored by Institut Jules Bordet. Primary endpoint: 3-year Recurrence-Free Survival in HER2-enriched subjects who achieve a pCR. Started Jan 2022; status: terminated.
02
Drugs
trastuzumab + pertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04675827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04675827.